TargEDys, a Rouen, France-based developer of solutions to regulate appetite, raised €5.8m in Series A funding.
The round was led jointly by Seventure Partners, NCI and Pontifax.
The company intends to use the funds to launch human clinical studies for its products targeting high appetite leading to overweight, and low appetite leading to malnourishment in elderly people, cachexia and anorexia.
Based on research from co-founders Serguei Fetissov and Pierre Déchelotte, and led by CEO Grégory Lambert, TargEDys uses scientific discoveries to develop functional food, medical food and pharmaceutical products to harness the microbiome’s ability to regulate appetite and thus maintain or restore metabolic health.
The first product will target overweight people while the second one will increase appetite in elderly, cachexic and anorexic patients.